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Aim. Our study aimed to determine prognostic factors for survival and recurrence in myxoﬁbrosarcomas based on the experience
of a single institution. Methods. Patients who had been diagnosed with a myxoﬁbrosarcoma were identiﬁed from our database.
Survival and recurrence were evaluated with Kaplan Meier survival curves for univariate and cox regression for multivariate
analysis. Results. 174 patients with a diagnosis of myxoﬁbrosarcoma were identiﬁed. Two patients were excluded due to incomplete
information, leaving 172 patients with a mean age of 67 years. Surgery was undertaken in all but 6 patients. Five-year survival was
better for myxoﬁbrosarcomas when compared to other soft tissue sarcomas (63% versus 57%). Size, grade of tumour, age, and
metastases were all found to be prognostic factors. Local recurrence occurred in 29 patients (17%) with an overall risk of 15% at
5 years. Previous inadvertent excision signiﬁcantly raised this risk to 45%. Wide surgical margins and depth of tumour, however,
had no impact on recurrence. Conclusion. Factors previously identiﬁed as prognostic did not demonstrate such a relationship in
our study, highlighting the unpredictable nature of myxoﬁbrosarcomas. Future treatment may lie in developing an understanding
molecular basis of the tumour and directing therapies accordingly.
1.Introduction
The World Health Organisation describes myxoﬁbrosarco-
mas as a spectrum of malignant ﬁbroblastic lesions with
variably myxoid stroma and pleomorphism, possessing a
distinctively curvilinear vascular pattern [1]. They are one
of the most common soft tissue tumours in the extremities
of elderly patients and are notorious for their high rate
of local recurrence. They are often higher grade than at
presentation,therefore,leadingtoagreaterriskofmetastases
[2], which is currently refractory to current nonsurgical
treatment options [3]. Recurrence has been shown to occur
in spite of repeated surgery involving wide local excision and
negative surgical margins [4].
The aim of this study was to examine a large single
institution experience to determine prognostic factors for
survivalandrecurrenceandcomparethiswiththeﬁndingsof
other recently published large series from single institutions.
In addition, comparison will also be made with the the
results of myxoﬁbrosarcomas and other types of STS at our
institution.
2. Method
Since1986,prospectivelykeptelectronicpatientrecordshave
been maintained at our institution, and as the diagnosis
of myxoﬁbrosarcoma was only popularised since the early
1990’s, the ﬁrst patient entered into this study was seen in
1993. Patients with a diagnosis of myxoﬁbrosarcoma were
identiﬁed and the size, grade, and depth of the tumour at
presentation, recurrence, and mortality were reviewed for all
of these patients.
A total of 174 patients were identiﬁed, of which complete
information was available on 172 patients, which formed the
study group. A total of 66 patients (38%) had undergone
a previous inadvertent excision of a myxoﬁbrosarcoma at
another institution prior to referral to our unit, with the
remaining 108 patients being newly diagnosed in our unit.
The mean age at presentation was sixty-seven years old
(range, ﬁfteen to ninety-three years old). The mean maxi-
mum size of tumour excised was 8.4 centimetres (range, 0.3–
31cm). The majority of the tumours in the study population2 Sarcoma
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Figure 1: Age distribution histogram with normal distribution
comparison showing a skewed population, being more frequent in
the >75-year-old population.
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Figure 2: Kaplan Meier survival curve for myxoﬁbrosarcoma com-
pared with other STS with time in months from diagnosis (P =
0.01).
were histologically high grade (n = 87/172, 51%) and were
deep to fascia in location (n = 93/172, 54%).
To assess the characteristics of myxoﬁbrosarcomas, the
dataset was analysed from a larger dataset of 2461 patients
all histological subtypes of STS seen in our unit until 2007,
which allowed comparison of demographic details, local
recurrence and survival rates of patients with myxoﬁbrosar-
coma.
Survival and recurrence were evaluated with Kaplan
Meier survival curves for univariate and cox regression for
multivariate analysis. Factors assessed included size, site,
location, margins, grade and depth were analysed.
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Figure 3: The eﬀect of unplanned excision on locally recurrent dis-
ease, with the cumulative risk of LR rising from 15% at 5 years for
those tumours primarily treated at our unit to 45% at 5 years for
those treated with a previously unplanned sarcoma excision (P =
0.0009).
3. Results
The mean and median age of the study population was
similar at 67 and 68 years respectively, with the mode being
78 years old, suggesting a skewed age distribution (Figure 1).
The mean age was also signiﬁcantly greater than the mean
age for all subtypes of STS seen in our unit (67 years versus
53 years, P<0.001). There was a signiﬁcantly higher pro-
portion of superﬁcial tumours seen compared to all other
histological subtypes of STS seen in our unit (46% versus
26%, P<0.001). The proportion of tumours which were
myxoﬁbrosarcoma presenting with high grade tumours was
signiﬁcantly lower than other types of STS (51% versus
57%, P = 0.001) (Table 3). The group of myxoﬁbrosarcoma
patients were more likely to be distributed in the arm or leg
than other STS subtypes.
The overall survival of those patients with myxoﬁbrosar-
coma was signiﬁcantly better than other types of STS, with
5-year survival being 63% versus 57% for all presentations
(P = 0.01, Figure 2). Metastases were present at diagnosis
in 6 patients (n = 6/174, 4%) and developed subsequently
in 35 patients (n = 35/174, 20%). Metastases developed sub-
sequenttolocallyrecurrentdiseasein12patients(n = 12/35,
34%) and as an isolated event in 23 patients (n = 23/35,
64%) (Figure 4).
Locally recurrent disease occurred in 29 patients (n =
29/172, 17%) but was signiﬁcantly more likely to occur
if there was a previous unplanned excision of the tumour
(cumulative risk of LR was 15% at 5 years compared to 45%
following previous excision, P = 0.0009). Other univariate
factors for development of locally recurrent disease were
grade of tumour, where lower grade tumours were more
likely to recur than high-grade tumours (LR rate for low
grade = 22%, intermediate grade = 28%, high grade = 8%,Sarcoma 3
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Figure 4: Histogram demonstrating location of myxoﬁbrosarco-
mas.
P = 0.007) and anatomical site (P = 0.03) but interestingly
wide surgical margins and depth of tumour were not prog-
nostic for locally recurrent disease, even for those patients
who were diagnosed and treated only in our unit. Patients
who had undergone a previous unplanned excision had
signiﬁcantly lower grade tumours (P = 0.006), which were
superﬁcial (P = 0.008) and smaller (newly diagnosed had
a mean size of 9.9cm compared to 5.9cm in the previously
excised group, P<0.001). On Cox regression multivariate
analysis for development of locally recurrent disease the only
prognostic factor was previous surgery (P = 0.03, HR = 5),
withfootandanklelocation tending tosigniﬁcance(P = 0.1,
HR = 4).
The type of treatment was excision alone in 133 patients
(73%), excision with split skin grafting in 26 patients (15%),
excision and endoprosthetic replacement in one patient, and
amputation in 6 patients (4%), and no deﬁnitive surgery
was undertaken in 6 patients (4%) (Figure 3). Amputation
was not more likely if the patient had undergone a previous
excision. Surgical margins in the patients treated primarily
in our unit were intralesional in 26%, marginal in 50%, and
wide in 24%. Of the 21 patients with intralesional margins, 8
patientsunderwentfurtherlocalisedexcision,achievingwide
margins and 1 patient underwent an amputation, achieving
a marginal margin, all those with intralesional underwent
postoperative prophylactic radiotherapy. Local recurrence
occurred in 5 patients with intralesional margins (24%), all
of whom had undergone a further excision to extend the
margins (Table 1).
The standard treatment was for postoperative radiother-
apy (55Gy) in all patients with deep, high-grade tumours,
greater than 5cm in size or those with poor margins. This
was undertaken 6 weeks after operation and for all patients
to have a scar reexcision and postoperative radiotherapy for
those patients with a previous attempted excision before
presentation to our unit (Table 2).
The only univariate prognostic factors for survival were
grade of tumour (P = 0.01) and development of metastases
Table 1: Prognostic factors for local recurrence and survival.
Local recurrence
Univariate prognostic factors Multivariate Prognostic Factors
Previous unplanned excision
Lower grade tumours Previous surgery
Survival
Univariate prognostic factors Multivariate Prognostic Factors
Grade of tumours
Development of metastases
Not developing metastases
Age at diagnosis
Size at resection
Table 2: Patient and disease characteristics.
Characteristic Value
Total 174
Newly diagnosed 108 (62%)
Previous excision 66 (38%)
Mean age (yrs) 67 (range: 15–93)
Depth
Superﬁcial 79 (46%)
Deep 23 (13%)
Mean tumour size (cm) 8.4 (range: 0.3–31)
New diagnosis 9.9
Previous excision 5.9
Grade
High 87 (51%)
Intermediate 62 (36%)
Low 23 (13%)
Metastases 41 (24%)
At diagnosis 6 (3%)
Following diagnosis 35 (20%)
Local recurrence at 5-year cumulative risk
Planned excision 15%
Unplanned excision 45%
Risk of local recurrence by tumour grade
Low 22%
Intermediate 28%
High 8%
Surgical margins
Wide 24%
Marginal 50%
Intralesional 26%
(P>0.0001). Locally recurrent disease, site, surgical mar-
gins, previous excision, and depth had no eﬀect on survival.
Independent prognostic factors on multivariate analysis for
survival were not developing metastases (P = 0.002, HR =
0.39), age at diagnosis (P = 0.002, HR = 1.03), and size at
resection (P = 0.01, HR = 1.1) (Table 1).
4. Discussion
Tumours now recognised as myxoﬁbrosarcomas were ini-
tially described as the myxoid variant of malignant ﬁbrous4 Sarcoma
Table 3: Myxoﬁbrosarcoma versus other soft tissue sarcomas.
Characteristic Myxoﬁbrosarcoma Other Soft tissue
sarcomas
Mean age (yrs) 67 53
Superﬁcial tumours (%) 46 26
Presenting with a higher
grade tumour (%) 51 57
5-year survival (%) 63 57
histiocytoma. It was not until the work of Angervall et al. [5]
that the term myxoﬁbrosarcoma was ﬁrst used to describe
this soft tissue tumour. Traditionally regarded as one of the
most frequently encountered sarcomas in elderly patients,
it is recognised by the World Health Organisation [1]. It is
most commonly reported to occur in the extremities, whilst
occasionally occurring in the trunk or head region, which is
all supported by our data.
Myxoﬁbrosarcomas are classiﬁed into two categories [3,
6]:superﬁcialanddeep.Superﬁciallesionsarethoseregarded
as being in the dermal or subcutaneous layer, whereas deep
lesions are either intramuscular or subfascial. Superﬁcial
lesions tend to inﬁltrate, whereas deep lesions form a single
discrete mass with a nodular appearance that spreads in
a longitudinal manner [2]. Numerous studies have shown
myxoﬁbrosarcomastohaveahigherrateofsuperﬁciallesions
compared to other soft tissue sarcomas [4, 6, 7], which is
supported by our data.
Local recurrence of myxoﬁbrosarcomas is a widely
reported phenomenon and has been reported as high as
61% [7], which is higher than that of other soft tissue
sarcomas [8]. Our series, however, demonstrated that local
recurrence rates for newly diagnosed tumours are similar
to many soft tissue sarcoma subtypes. Often these lesions
may be mistaken for other inﬂammatory processes such
as myxoid liposarcomas, low-grade ﬁbromyxoid sarcomas,
cellular myxomas, and nodular fasciitis [4, 9]. This is
demonstrated in our series, with a high rate of patients
presenting who had had a previous inadvertent excision.
These tumours were smaller, more superﬁcial, and lower
grade when compared to newly diagnosed patients. The
diﬃculties in identifying these lesions, inevitably, impacted
the ability to establish an initial accurate diagnosis. Current
consensus is that the lack of pseudocapsule in the superﬁcial
subtype allows myxoﬁbrosarcomas to exhibit the ability to
extend along fascial planes to involve surrounding tissues
resulting in inadequate excision. This goes someway to
explaining the high rate of locally recurrent disease in the
previous excision subgroup; as this group is more likely
to have higher intralesional excision rate and a greater
proportion of more superﬁcial tumours. The deeper discrete
tumours are, the easier they are to identify and less likely to
be operated upon by a nonsarcoma specialist.
Various factors have been identiﬁed as being important
in inﬂuencing recurrence rates: size, location, myxoid com-
ponent, and age. Our data showed that the only statistically
signiﬁcant factor for local recurrence was when there had
been a previous inadvertent excision. Our results show that
those patients treated elsewhere or in our unit with an
intralesional margin have high rates of local recurrence even
when a wide margin is ﬁnally achieved with further re-
excision. Nevertheless, our feeling remains that tumour-free
surgical margins at ﬁrst excision are important as have been
previously demonstrated [9–11], but greater numbers are
needed in our study to demonstrate signiﬁcance.
As is typical for most soft tissue sarcomas: larger,
high grade, and deep tumours have a poorer prognosis.
Whereas, previous studies have shown that tumor grade is
not associated with frequency of local recurrence [3, 4],
our study shows that this is a univariate prognostic factor.
Its ability to recur at higher grades is likely to be the
cause of this. It has been postulated that myxoﬁbrosarcomas
gradually become more cellular, more pleomorphic, more
mitotically active, and more necrotic [3]. The tendency
of low-grade lesions to recur at higher grades underlines
the need for accurate diagnosis and excision in specialist
centres due to the potential for development of metastatic
disease [3]. It should, however, be noted that our data,
unlike other studies, showed that in the majority of cases,
metastatic disease was a solitary disease relapse and was
only subsequent to local relapse in approximately one-
third of cases. Metastatic myxoﬁbrosarcomas are frequently
refractory to current treatment strategies and constitute the
primary cause of sarcoma related death [3, 12].
The natural history of myxoﬁbrosarcomas and its ten-
dency to recur as higher grade lesions with a potential to
metastise means that overall survival is likely to be linked
to recurrence. The ﬁve- and ten-year survival rates demon-
strated in our series (63% and 42% resp.) were comparable
to that of other studies [6, 13]. Locally recurrent disease,
however, was not an independent prognostic factor for
survival in our series. Nevertheless, decreasing the rate of
local recurrence is of paramount importance. The results
clearly show a poorer rate of local control in the group
of inadvertently excised tumours. This may be achieved by
improving diagnosis, expediting early referral to a sarcoma
centres and ensuring wide tumour-free surgical margins in
superﬁcial tumours. This in part involves better surgical
planning through detailed imaging prior to surgery [14].
However, in order to develop new treatment strategies and
improvesurvivalinthelongterm,agreaterunderstandingof
the molecular basis of metastatic spread may help to achieve
this.
Current work has focused upon the overexpression of
MET and ezrin. MET, a cell receptor, represents the ligand
for hepatocyte growth factor (HGF), which is responsible
for epithelial cell dissociation, invasion, and angiogenesis
[15, 16]. MET overexpression has been identiﬁed in numer-
ous human tumours, and its tumorigenic properties have
recently been demonstrated in osteosarcomas, where it is
abletodrivethetransformationofosteoblastsintomalignant
cells [17]. The MET oncogene has also been shown to be
inﬂuential in myxoﬁbrosarcomas. It is predictive of shorter
overallsurvivalandmetastasis-freesurvivalaswellastumour
size and mitotic rate [18]. As a result, this represents an
appealing future therapeutic target and research has been
targeted to achieve this goal. Cassinelli et al. [19] utilisedSarcoma 5
mice to replicate a lung-metastasizing human tumor model
demonstrating inhibition of MET activation and signaling in
lung cell carcinomas. Thereby, demonstrating that MET tar-
geting is a viable future therapeutic option in the treatment
of metastatic cancer.
The exact upstream mechanism of action of MET in
myxoﬁbrosarcomas remains unclear, but it may be related to
ezrin. Their relationship has previously been demonstrated.
Overexpression of ezrin, a protein known to play a key role
in cancer metastasis, has already been shown to result in
disease progression and metastasis in a number of cancers
including osteosarcomas [18] and rhabdomyosarcomas [20].
With respect to myxoﬁbrosarcomas, Huang et al. demon-
strated that ezrin overexpression was associated with higher
tumor grade as well as being a poor prognosticator of
disease-speciﬁc survival and metastasis-free survival. Hence,
those tumours found to overexpress that ezrin should be
monitored closely postoperatively [21].
Myxoﬁbrosarcomas present a challenging management
conundrum due to their unpredictable clinical course. Cur-
rently, ensuring tumour-free surgical margins is of para-
mount importance. However, the future of management of
this tumor lies in developing a greater understanding of the
molecular basis of this tumor to develop and direct therapy
accordingly.
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